Vinay Prasad

Associate Professor

  • 3094 Citations
  • 28 h-Index
20092019
If you made any changes in Pure, your changes will be visible here soon.

Research Output 2009 2019

Filter
Letter
2019
1 Citation (Scopus)

Characteristics of Public Comments Submitted to State Health Technology Assessment Programs in Oregon and Washington

Ahn, R., Herrera-Perez, D. & Prasad, V., Jan 1 2019, (Accepted/In press) In : JAMA Internal Medicine.

Research output: Contribution to journalLetter

Biomedical Technology Assessment

Concerning survival signal for eltrombopag in MDS/AML

Tao, D. & Prasad, V., Jan 1 2019, (Accepted/In press) In : Leukemia and Lymphoma.

Research output: Contribution to journalLetter

Reply to C.J. Sweeney et al

Parikh, R. B. & Prasad, V., Jan 1 2019, In : Journal of Clinical Oncology. 37, 19, p. 1680-1681 2 p.

Research output: Contribution to journalLetter

The Clinical Trials Portfolio for On-label and Off-label Studies of Eculizumab

Kim, M. S. & Prasad, V., Jan 1 2019, (Accepted/In press) In : JAMA Internal Medicine.

Research output: Contribution to journalLetter

Clinical Trials
eculizumab

The Reply

Mandrola, J., Cifu, A., Prasad, V. & Foy, A., Sep 2019, In : American Journal of Medicine. 132, 9, p. e719

Research output: Contribution to journalLetter

2018
1 Citation (Scopus)

Brentuximab vedotin for frontline Hodgkin lymphoma: How much will a successful trial cost patients and payers?

Shanbhag, S. & Prasad, V., Nov 1 2018, In : European Journal of Cancer. 104, p. 252-253 2 p.

Research output: Contribution to journalLetter

Hodgkin Disease
Costs and Cost Analysis
cAC10-vcMMAE
1 Citation (Scopus)

Cost-effectiveness of nusinersen for spinal muscular atrophy: Reply

Prasad, V., Jul 1 2018, In : JAMA Pediatrics. 172, 7, p. 701-702 2 p.

Research output: Contribution to journalLetter

Spinal Muscular Atrophy
Cost-Benefit Analysis
1 Citation (Scopus)

Crossover is not associated with faster trial accrual

Chen, E. Y. & Prasad, V., Mar 1 2018, In : Annals of Oncology. 29, 3, p. 776-777 2 p., mdx821.

Research output: Contribution to journalLetter

1 Citation (Scopus)

Inconsistent reporting of potential conflicts of interest

Prasad, V., Jul 24 2018, In : JAMA - Journal of the American Medical Association. 320, 4, 1 p.

Research output: Contribution to journalLetter

Conflict of Interest

Inconsistent Reporting of Potential Conflicts of Interest

Prasad, V., Oct 1 2018, In : JAMA Internal Medicine. 178, 10, p. 1424-1425 2 p.

Research output: Contribution to journalLetter

Conflict of Interest

Inconsistent Reporting of Potential Conflicts of Interest

Prasad, V., Sep 1 2018, In : JAMA Pediatrics. 172, 9, 1 p.

Research output: Contribution to journalLetter

Conflict of Interest
1 Citation (Scopus)

Inconsistent Reporting of Potential Conflicts of Interest

Prasad, V., Oct 1 2018, In : JAMA oncology. 4, 10, 1 p.

Research output: Contribution to journalLetter

Conflict of Interest
1 Citation (Scopus)

In reply

Prasad, V., Kaestner, V. & Mailankody, S., Sep 1 2018, In : JAMA oncology. 4, 9, p. 1300-1301 2 p.

Research output: Contribution to journalLetter

1 Citation (Scopus)

In reply

Prasad, V. & Mailankody, S., Apr 1 2018, In : JAMA Internal Medicine. 178, 4, p. 588-589 2 p.

Research output: Contribution to journalLetter

2 Citations (Scopus)

In reply

Mailankody, S. & Prasad, V., Apr 1 2018, In : JAMA oncology. 4, 4, p. 586-587 2 p.

Research output: Contribution to journalLetter

24 Citations (Scopus)

Total costs of chimeric antigen receptor T-cell immunotherapy

Hernandez, I., Prasad, V. & Gellad, W. F., Jul 1 2018, In : JAMA oncology. 4, 7, p. 994-996 3 p.

Research output: Contribution to journalLetter

T-Cell Antigen Receptor
Immunotherapy
Costs and Cost Analysis
2017
3 Citations (Scopus)

A further strategy to combat the high price of anticancer drugs

Prasad, V., De Jesús, K. & Mailankody, S., Oct 1 2017, In : Nature Reviews Clinical Oncology. 14, 10, 1 p.

Research output: Contribution to journalLetter

Pharmaceutical Preparations
3 Citations (Scopus)

Clinically meaningful benefit: Real world use compared against the American and European guidelines

Dreicer, J. J., Mailankody, S., Fahkrejahani, F. & Prasad, V., Dec 1 2017, In : Blood Cancer Journal. 7, 12, 645.

Research output: Contribution to journalLetter

Guidelines
3 Citations (Scopus)

Conflicts of interest in Twitter

Kaestner, V., Brown, A., Tao, D. & Prasad, V., Sep 1 2017, In : The Lancet Haematology. 4, 9, p. e408-e409

Research output: Contribution to journalLetter

Conflict of Interest
3 Citations (Scopus)

Financial conflicts of interest among editorialists in high-impact journals

Kaestner, V. & Prasad, V., Sep 15 2017, In : Blood Cancer Journal. 7, 9, p. e611

Research output: Contribution to journalLetter

Conflict of Interest
15 Citations (Scopus)

Financial conflicts of interest among hematologist-oncologists on Twitter

Tao, D. L., Boothby, A., McLouth, J. & Prasad, V., Mar 1 2017, In : JAMA Internal Medicine. 177, 3, p. 425-427 3 p.

Research output: Contribution to journalLetter

Conflict of Interest
Oncologists
2 Citations (Scopus)

In reply

Beer, T. T. & Prasad, V., Nov 1 2017, In : JAMA oncology. 3, 11, p. 1588-1589 2 p.

Research output: Contribution to journalLetter

Hematology
Industry
Medicine
9 Citations (Scopus)

The rising price of cancer drugs- a newold problem?

Prasad, V., Wang, R., Afifi, S. H. & Mailankody, S., Feb 1 2017, In : JAMA oncology. 3, 2, p. 277-278 2 p.

Research output: Contribution to journalLetter

Pharmaceutical Preparations
Neoplasms
1 Citation (Scopus)
Drug Approval
Publications
Food
Pharmaceutical Preparations
Neoplasms
1 Citation (Scopus)

To the editor

Friedberg, M. W., Gellad, W. F. & Prasad, V., Jul 1 2017, In : JAMA Internal Medicine. 177, 7, p. 1058 1 p.

Research output: Contribution to journalLetter

To the Editor

Redberg, R. F. & Prasad, V., Aug 24 2017, In : New England Journal of Medicine. 377, 8, p. 786-787 2 p.

Research output: Contribution to journalLetter

2016
7 Citations (Scopus)

Future jobs of FDA's haematology-oncology reviewers

Bien, J. & Prasad, V., 2016, In : BMJ (Online). 354, i5055.

Research output: Contribution to journalLetter

Hematology
16 Citations (Scopus)

Industry Funding of Cancer Patient Advocacy Organizations

Abola, M. V. & Prasad, V., Nov 1 2016, In : Mayo Clinic Proceedings. 91, 11, p. 1668-1670 3 p.

Research output: Contribution to journalLetter

Patient Advocacy
Industry
Organizations
Neoplasms
21 Citations (Scopus)

The Use of Superlatives in Cancer Research

Abola, M. V. & Prasad, V., Jan 1 2016, In : JAMA oncology. 2, 1, p. 139-141 3 p.

Research output: Contribution to journalLetter

Marketing of Health Services
Consumer Health Information
Mass Media
Antineoplastic Agents
Biomedical Research
2015
30 Citations (Scopus)

Authorship inflation in medical publications

Tilak, G., Prasad, V. & Jena, A. B., 2015, In : Inquiry. 52

Research output: Contribution to journalLetter

Authorship
Economic Inflation
Publications
Growth
Population Density
138 Citations (Scopus)

Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs

Mailankody, S. & Prasad, V., Jul 1 2015, In : JAMA oncology. 1, 4, p. 539-540 2 p.

Research output: Contribution to journalLetter

Device Approval
Diffusion of Innovation
Drug Approval
Drug Costs
Economic Inflation

Pricing and Value of Cancer Drugs--Reply

Mailankody, S. & Prasad, V., Sep 1 2015, In : JAMA oncology. 1, 6, p. 842-843 2 p.

Research output: Contribution to journalLetter

Device Approval
Diffusion of Innovation
Drug Costs
Antineoplastic Agents
2014
3 Citations (Scopus)

Exemestane with varian suppression in premenopausal Breast Cancer

Prasad, V., Oct 2 2014, In : New England Journal of Medicine. 371, 14, p. 1358 1 p.

Research output: Contribution to journalLetter

exemestane
Androstadienes
Antineoplastic Combined Chemotherapy Protocols
Triptorelin Pamoate
Tamoxifen
2013

Firearm legislation and gun-related fatalities

Jena, A. B., Sun, E. C. & Prasad, V., Nov 25 2013, In : JAMA Internal Medicine. 173, 21, 1 p.

Research output: Contribution to journalLetter

Firearms
Legislation